AntriaBio

Investors

Press Releases

Oct 17, 2017 AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema
Oct 9, 2017 AntriaBio Appoints Nektar Therapeutics CFO to its Board of Directors
Oct 4, 2017 AntriaBio Appoints Dr. Robert Bhisitkul to its Scientific Advisory Board
Aug 7, 2017 AntriaBio and ActiveSite Pharmaceuticals Announce License and Development Agreement for Plasma Kallikrein Inhibitors
Jul 25, 2017 AntriaBio Announces First Patient Dosed in Phase 1 Clinical Study of AB101
Jul 17, 2017 AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month
Jun 5, 2017 AntriaBio Files Investigational New Drug Application for Once-Weekly Basal Insulin AB101
May 1, 2017 AntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101
Mar 22, 2017 AntriaBio Appoints Two Pharmaceutical Executives to its Board of Directors
Dec 15, 2016 AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock

<< Previous
1
2
3
4
5
6
7
8
Next >>

Show All